MetaCap

uniQure N.V. (QURE) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sarepta Therapeutics (SRPT) has outperformed uniQure N.V. (QURE) over the past year, losing 24.6% versus a loss of 30.4%. Over five years, QURE leads with a -32.9% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.36 billion), about 1.1 times the size.

Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -1236.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QURE-30.42%SRPT-24.65%
+91%+8%-75%
Nov 21, 20251 yearNov 20, 2026
QURE-34.72%SRPT-83.34%
+139%+21%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QURE versus SRPT key metrics
MetricQURESRPT
Share price$19.35$13.33
Market cap$1.36B$1.43B
1-day change-4.35%-5.93%
YTD return-19.14%-38.06%
1-year return-30.42%-24.65%
5-year return-32.86%-83.26%
P/E ratio (TTM)—666.50
Forward P/E—8.87
EPS (TTM)$-3.51$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$16.10M$2.20B
Revenue growth (YoY)-40.64%+15.58%
Net income (latest FY)$-198.97M$-713.41M
Gross margin89.53%98.84%
Operating margin-1151.38%-31.83%
Net margin-1236.00%-32.45%
52-week high$51.72$24.68
52-week low$8.73$13.25
Distance from 52-week high-62.59%-45.99%
Analyst consensusstrong_buyhold
Avg. price target upside+207.03%+63.32%
Average volume2.26M2.70M
Shares outstanding70.14M107.24M
Employees221835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Sarepta Therapeutics is more profitable, keeping -32.5 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
  • Sarepta Therapeutics grew revenue faster in its latest fiscal year (+15.58% vs -40.64%).

About uniQure N.V.

QURE stock →

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

QURE vs SRPT FAQ

Which is bigger, uniQure N.V. or Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.36B for uniQure N.V. (QURE).

Which stock has performed better over the past year, QURE or SRPT?

SRPT returned -24.65% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.

Are uniQure N.V. and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons